EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis

Marcos Niedziewski Goularte iD, Mariany Hatori Miyamoto iD, Marcelo Pitombeira de Lacerda iD

European Journal of Haematology · 2026-07 · 117 (1) · 88-99

DOI: 10.1111/ejh.70175 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Haematology, online erschienen am 25.03.2026. Verfasst von Marcos Niedziewski Goularte und 2 weiteren Autor:innen. Beteiligte Einrichtung: Universidade da Região de Joinville-UNIVILLE, SC, Brazil. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the efficacy and safety of venetoclax combined with intensive chemotherapy regimens in patients with relapsed or refractory acute myeloid leukemia (R/R AML) through a systematic review and single‐arm meta‐analysis.

Methods

A systematic search of PubMed, Embase, and Cochrane CENTRAL was conducted from inception to January 2025. Non‐randomized studies enrolling R/R AML patients treated with venetoclax plus intensive chemotherapy were included. Pooled rates of complete remission (CR), composite complete remission (CRc), overall response rate (ORR), and adverse events were estimated using random‐effects models. Heterogeneity was assessed with I 2 statistics, and sensitivity and subgroup analyses were performed according to chemotherapy regimen.

Results

Six retrospective studies comprising 235 patients were included. The pooled CR rate was 27.0% (95% CI, 9.18–57.50; I 2 = 84.6%), CRc rate was 51.45% (95% CI, 36.15–66.76; I 2 = 83.5%), and ORR was 63.79% (95% CI, 49.67–77.92; I 2 = 82.0%). Febrile neutropenia occurred in 71.38% and pneumonia in 23.6% of patients.

Conclusions

Venetoclax combined with intensive chemotherapy demonstrates meaningful antileukemic activity in R/R AML, with an expected toxicity profile. Prospective trials are warranted to define its role relative to standard salvage therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicSulfonamidesHumansTreatment OutcomeRecurrenceRemission Induction

Stichwörter der Autor:innen

acute myeloid leukemiaantineoplastic combined chemotherapy protocolsmeta‐analysissystematic reviewvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Universidade da Região de Joinville-UNIVILLE, SC, Brazil.
  • Departamento de Hematologia e Oncologia, Hospital Municipal São José, SC, Brazil.

ORCID-Profile: Marcos Niedziewski Goularte, Mariany Hatori Miyamoto, Marcelo Pitombeira de Lacerda

Zitieren

APA

Goularte, M. N., Miyamoto, M. H., & de Lacerda, M. P. (2026). Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis. European Journal of Haematology, 117(1), 88-99. https://doi.org/10.1111/ejh.70175

Vancouver

Goularte MN, Miyamoto MH, de Lacerda MP. Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis. European Journal of Haematology. 2026;117(1):88-99. doi:10.1111/ejh.70175

BibTeX
@article{Goularte2026,
  author = {Goularte, Marcos Niedziewski and Miyamoto, Mariany Hatori and de Lacerda, Marcelo Pitombeira},
  title = {Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {1},
  pages = {88--99},
  doi = {10.1111/ejh.70175}
}
Kostenlos starten →